ReviewRadiology2012
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play.
Review in Radiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it, 208 citations in OpenAlex.
- Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.BMC geriatrics · 2016Pooled it
- Bibliometric analysis of neural injury biomarkers in neurodegenerative diseases: research trends and future perspectives.Frontiers in human neuroscience · 2025Article
- Alzheimer's Disease Protein Targets: Comprehensive Review and Future Directions.Current pharmaceutical design · 2025Review
- Comparison of Inter-Method Agreement and Reliability for Automatic Brain Volumetry Using Three Different Clinically Available Software Packages.Medicina (Kaunas, Lithuania) · 2024Article
- Personalized medicine in old age psychiatry and Alzheimer's disease.Frontiers in psychiatry · 2024Review
- Metabolite Variations in the Hippocampus and Corpus Callosum of Patients with Mild Cognitive Impairment Using Magnetic Resonance Spectroscopy with Three-Dimensional Chemical Shift Images.Brain sciences · 2023Article
- Prediction of Amyloid β-Positivity with both MRI Parameters and Cognitive Function Using Machine Learning.Journal of the Korean Society of Radiology · 2023Article
- Mathematical modeling of human memory.Frontiers in psychology · 2023Review
- Regularized Buckley-James method for right-censored outcomes with block-missing multimodal covariates.Stat (International Statistical Institute) · 2022Article
- Agreement and Reliability between Clinically Available Software Programs in Measuring Volumes and Normative Percentiles of Segmented Brain Regions.Korean journal of radiology · 2022Article
- [Brain MRI-Based Artificial Intelligence Software in Patients with Neurodegenerative Diseases: Current Status].Taehan Yongsang Uihakhoe chi · 2022Review
- BACE1: A Key Regulator in Alzheimer's Disease Progression and Current Development of its Inhibitors.Current neuropharmacology · 2022Review
- Neuroimaging Markers for Determining Former American Football Players at Risk for Alzheimer's Disease.Neurotrauma reports · 2022Article
- Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay.Journal of nanobiotechnology · 2021Article
- [Expert Opinions and Recommendations for the Clinical Use of Quantitative Analysis Software for MRI-Based Brain Volumetry].Taehan Yongsang Uihakhoe chi · 2021Review
- Article
- Clinically Available Software for Automatic Brain Volumetry: Comparisons of Volume Measurements and Validation of Intermethod Reliability.Korean journal of radiology · 2021Article
- Article
- Advances in multimodal data fusion in neuroimaging: Overview, challenges, and novel orientation.An international journal on information fusion · 2020Article
- Ultrasonic Assessment of the Medial Temporal Lobe Tissue Displacements in Alzheimer's Disease.Diagnostics (Basel, Switzerland) · 2020Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Alzheimer disease (AD) is one of, if not the most, feared diseases associated with aging. The prevalence of AD increases exponentially with age after 60 years. Increasing life expectancy coupled with the absence of any approved disease-modifying therapies at present position AD as a dominant public health problem. Major advances have occurred in the development of disease biomarkers for AD in the past 2 decades. At present, the most well-developed AD biomarkers are the cerebrospinal fluid analytes amyloid-β 42 and tau and the brain imaging measures amyloid positron emission tomography (PET), fluorodeoxyglucose PET, and magnetic resonance imaging. CSF and imaging biomarkers are incorporated into revised diagnostic guidelines for AD, which have recently been updated for the first time since their original formulation in 1984. Results of recent studies suggest the possibility of an ordered evolution of AD biomarker abnormalities that can be used to stage the typical 20-30-year course of the disease. When compared with biomarkers in other areas of medicine, however, the absence of standardized quantitative metrics for AD imaging biomarkers constitutes a major deficiency. Failure to move toward a standardized system of quantitative metrics has substantially limited potential diagnostic usefulness of imaging in AD. This presents an important opportunity that, if widely embraced, could greatly expand the application of imaging to improve clinical diagnosis and the quality and efficiency of clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.